FRME:NASDAQFirst Merchants Corporation Analysis
Data as of 2026-04-04 - not real-time
$39.43
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
First Merchants (FRME) trades around $39.43, comfortably above its 20‑day SMA ($37.53) and 200‑day SMA ($38.59), while the RSI of 60 and a bullish MACD histogram suggest modest upward momentum. Its forward P/E of 8.7 is well below the industry average of 16.6, indicating a valuation discount relative to peers. The dividend yield of 3.65% with a payout ratio under 40% points to a sustainable income stream, reinforced by strong operating cash flow. However, the DCF fair‑value estimate of $30.65 sits well under the current price, hinting at a potential overvaluation on a pure cash‑flow basis. The stock’s beta of 0.71 and a 30‑day volatility of 26% reflect a relatively defensive profile but with notable price swings. Upcoming earnings on April 22 will be a key catalyst, as analysts have a consensus “Buy” rating and a median target of $48, implying ~22% upside.
The balance sheet shows $1.07 B of debt offset by $0.33 B of cash, leaving a net debt position that warrants monitoring, especially in a sector sensitive to credit conditions. Operating margins are robust at 42.7% and profit margins at 35.2%, supporting earnings resilience. While the regional banking sector carries medium regulatory and credit risk, FRME’s geographic focus in the Midwest limits exposure to broader economic turbulence. Overall, the blend of attractive yield, solid fundamentals, and modest technical upside supports a positive outlook, though valuation concerns and upcoming earnings volatility temper enthusiasm.
The balance sheet shows $1.07 B of debt offset by $0.33 B of cash, leaving a net debt position that warrants monitoring, especially in a sector sensitive to credit conditions. Operating margins are robust at 42.7% and profit margins at 35.2%, supporting earnings resilience. While the regional banking sector carries medium regulatory and credit risk, FRME’s geographic focus in the Midwest limits exposure to broader economic turbulence. Overall, the blend of attractive yield, solid fundamentals, and modest technical upside supports a positive outlook, though valuation concerns and upcoming earnings volatility temper enthusiasm.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 7/10
Key Factors
- Technical momentum modestly bullish but price near short‑term resistance
- Upcoming earnings release could introduce volatility
- Sustainable dividend provides downside cushion
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Valuation discount vs industry P/E multiple
- Analyst median target price of $48 indicating ~22% upside
- Strong operating margins and cash flow supporting earnings growth
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Consistent dividend yield with low payout ratio
- Low beta and defensive profile for a regional bank
- Solid ROE and profit margins suggest enduring profitability
Key Metrics & Analysis
Financial Health
Revenue Growth-4.60%
Profit Margin35.22%
P/E Ratio10.2
ROE9.47%
ROA1.21%
P/B Ratio0.9
Op. Cash Flow$283.6M
Industry P/E16.6
Technical Analysis
TrendNeutral
RSI60.1
Support$35.71
Resistance$39.63
MA 20$37.53
MA 50$39.32
MA 200$38.59
MACDBullish
VolumeStable
Fear & Greed Index78.8
Valuation
Fair Value$30.65
Target Price$46.20
Upside/Downside17.17%
GradeFair
TypeValue
Dividend Yield3.65%
Risk Assessment
Beta0.71
Volatility26.28%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.